Health Economics›Gallbladder cancer›Metastatic or unresectable disease first-line therapy

Metastatic or unresectable disease first-line therapy

Gallbladder cancer · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
FELV Variant #01	—	R 2 934	21d	—	~12.0 mo	~2	~R 5 867 PFS proxy · indirect	—
CapeOx Variant #01	—	R 2 620	21d	~6.7 mo	~12.2 mo	~2	~R 5 240 PFS proxy · indirect	20
ECF Variant #01	—	R 2 442	21d	—	~9.4 mo	~6	~R 14 655 PFS proxy · indirect	4

3 of 3 regimens shown